Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of tretinoin added to methylprednisolone for paroxysmal nocturnal hemoglobinuria
ChiCTR2000039675Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tretinoin and methylprednisolone in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Platelet count, Red blood cell count and 5 more. Started Jan 2021; status: recruiting.
02
Drugs
tretinoinmethylprednisolone
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on ChiCTR2000039675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039675.